Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery
- Resource Type
- Authors
- Li-li Pei; Ying Guo; Han Chen; Li-Yong Zhong
- Source
- Journal of Pediatric Endocrinology and Metabolism. 36:484-491
- Subject
- Endocrinology
Endocrinology, Diabetes and Metabolism
Pediatrics, Perinatology and Child Health
- Language
- ISSN
- 2191-0251
0334-018X
Objectives Childhood-onset craniopharyngiomas (CPs) have a high incidence of growth hormone deficiency (GHD) leading to growth failure and metabolic disorders. We aim to evaluate the benefits and risks of recombinant human growth hormone replacement therapy (GHRT) in postoperative children. Methods We retrospectively analyzed auxological and metabolic parameters and adverse events before and after GHRT of 44 children after CP surgery. Results The median duration of GHRT was 24 months (IQR, 12.5–36). Growth velocity (GV) increased significantly after different treatment duration (TD) compared with baseline (p Conclusions GHRT effectively accelerates GV, increases HtSDS, and improves lipid profiles without unfavorable effects on glucose metabolism. The benefits are clear and the risks of adverse events are low.